FindTrial
Sign In

Iobenguane I-131

RADIATION2 trials

Sponsors

Children's Oncology Group

Conditions

GanglioneuroblastomaGanglioneuroblastoma, NodularLocalized Resectable NeuroblastomaLocalized Unresectable NeuroblastomaNeuroblastomaRegional NeuroblastomaStage 4 NeuroblastomaStage 4S Neuroblastoma

Phase 1

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
CompletedNCT01175356
Children's Oncology GroupGanglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma +3
Start: 2011-12-21End: 2025-12-31Updated: 2026-01-23

Phase 3

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RecruitingNCT03126916
Children's Oncology GroupGanglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Start: 2018-05-14End: 2030-09-30Target: 750Updated: 2026-02-27

Related Papers

Abstract A037 Changes in T-cell repertoire during high-risk neuroblastoma therapy: A report from the Children’s Oncology Group
Cancer Research2024-09-05
Inequitable Poverty Exposures: A Subspecialty Opportunity to Address Disparities
Hospital Pediatrics2024-01-195 citations
Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.
Journal of Clinical Oncology2023-06-016 citations
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
Nature Communications2023-05-0540 citations
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
Nature Medicine2023-04-03111 citations
A Structural Racism Framework to Guide Health Equity Interventions in Pediatric Oncology
PEDIATRICS2022-04-0712 citations
A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
Frontiers in Pediatrics2022-03-1026 citations
A safety and feasibility trial of <sup>131</sup>I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study
Pediatric Blood & Cancer2021-05-2437 citations